India’s Medtech Rise A New Global Innovation Hub

India’s medical technology sector is reaching a critical inflection point as the nation transitions from a hub of manufacturing and adaptation to a recognized source of global innovation. Identified as an “access-led innovator” in a new report by Bain & Company, India is demonstrating that its focus on affordability and scalability can lead to genuine global competitiveness.

Market Performance and Future Outlook:
The country’s medtech ecosystem is showing strong momentum, bolstered by the following key performance metrics and projections:

In the 2025 fiscal year, India’s medical device exports reached US$4 billion.

Imports of high-end medical devices currently stand at US$5.5 billion, representing a significant opportunity for domestic innovation.

Healthcare demand in India is projected to grow to over US$320 billion within the next couple of years at a compound annual growth rate (CAGR) of 10–12%.

The broader medtech opportunity in India is estimated to reach US$35 billion by 2030.

Medical device exports from India are expected to grow at a CAGR of over 20% through 2030, reaching US$8 billion.

Investment and Strategic Shifts:
Investor confidence in the Indian medtech sector has grown substantially as the industry moves toward higher-value innovation. The share of healthcare investment dedicated to medtech has increased from less than 10% before 2024 to 15–20% between 2024 and 2025. Experts note that India’s next phase of growth will be defined by its ability to build globally competitive innovation through stronger regulatory capabilities, commercialization strategies, and clinical evidence generation.

Navigating the Path to Global Scale:
While the foundations for growth are in place, the Bain & Company report highlights five structural areas that Indian and APAC medtech companies must strengthen to achieve global scale:

Funding: Addressing the capital gap that emerging companies face when moving from innovation to commercial scale.

Talent Development: Increasing access to professionals experienced in global regulatory pathways and international clinical trials.

Intellectual Property: Implementing effective global filing strategies to strengthen patent coverage.

Infrastructure: Building market-entry support and channel infrastructure to compete effectively in foreign markets.

Clinical Evidence: Generating the robust health-economic data required to support market adoption and revenue generation.

As the region continues to mature, investments made over the next 24 months are expected to determine the long-term role of Indian and APAC companies in the global medtech landscape. With strategic commitments to bridging the gap between innovation and commercialization, the region is well-positioned to become a leading exporter of medical innovation by 2030.